

SUMMARY

Summary in terms of Regulation 13(1B) of the Competition Commission of India (Procedure in regard to the Transaction of Business relating to Combinations) Regulations, 2011 (as amended)

a) Names of parties of the combination

1. Abbott Laboratories (**Abbott**) and St. Jude Medical, Inc. (**SJM**) are the parties to the combination. Along with the parties, two newly incorporated wholly owned subsidiaries of Abbott Laboratories – Vault Merger Sub, LLC and Vault Merger Sub, Inc. – are also parties to the Agreement and Plan of Merger (**Agreement**) executed on 27 April 2016, which governs the terms of Abbott's acquisition of SJM.

b) Type of the combination

2. The proposed combination relates to the acquisition of SJM by Abbott, hereinafter referred to as the **Proposed Combination**.

c) Area of activity of the parties to the combination

3. Abbott is a publicly traded global healthcare corporation devoted to improving life through the development of products and technologies in the healthcare segment.
4. Abbott has four principal divisions from which it derives its primary revenue. These are:

- a. **Nutritional Products:** These products include a broad line of pediatric and adult nutritional products manufactured, marketed, and sold worldwide.
- b. **Medical Devices:** These products include a broad line of coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease that are manufactured, marketed, and sold worldwide.
- c. **Diagnostic Products:** These products include a broad line of diagnostic systems and tests manufactured, marketed, and sold worldwide.
- d. **Established Pharmaceutical Products:** These products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States.

SJM:

- 5. SJM, together with its subsidiaries, focuses on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neuro-stimulation devices for the management of chronic pain and movement disorders.

d) Relevant markets to which the combination relates

- 6. Since the Parties are yet to complete their inquiry on possible

overlaps between their respective businesses, in accordance with Regulation 5(6) of the Combination Regulations, the Parties undertake to provide the requisite information, if any, as promptly as possible.